Previous 10 | Next 10 |
2023-10-26 12:07:25 ET Summary The business entered my High Quality and Bad Momentum Screener. War concerns have had limited impact on the company's sales and profitability, as most of its sales are from foreign markets. InMode revealed slashed EPS and revenue guidance for FY ...
2023-10-18 09:53:00 ET Diabetes care and aesthetics. Those are two areas of healthcare that should provide investors with ample growth opportunities in the long run. Two companies that are in solid positions to capitalize on that potential are DexCom (NASDAQ: DXCM) and InMode ...
2023-10-13 10:40:15 ET Summary InMode shares experienced a significant drop of 20% in one trading day, but the decline is seen as excessively harsh. InMode's unique product line bridges the gap between surgical procedures and standard laser treatments, making it stand out in the m...
InMode Files Patent Infringement Complaint Against BTL Industries, Inc. (d/b/a BTL Aesthetics) PR Newswire YOKNEAM, Israel , Oct. 13, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) , a leading global provider of innovative medical technologies,...
2023-10-12 13:26:41 ET More on Femasys, Jaguar Health, etc. Jaguar Health, Inc. (JAGX) Q2 2023 Earnings Call Transcript LogicMark, Inc. (LGMK) Q2 2023 Earnings Call Transcript Femasys regains Nasdaq compliance Jaguar Health's Napo Pharma gets patent in Japan ...
2023-10-12 09:12:24 ET More on InMode InMode: Bullish Support Failed To Materialize InMode: Strong Net Cash Position Sets The Stage For Opportunistic Buybacks InMode: Be Greedy When Others Are Fearful Biggest stock movers today: InMode, Tupperware Brands and ...
2023-10-12 08:22:14 ET More on Beyond Meat, SELLAS Life Sciences, etc. Beyond Meat Continues To Look Potentially Beyond Repair Beyond Meat: The Core Question Here Is Liquidity Beyond Meat: Pain Is Far From Over SELLAS gains on FDA orphan drug status for its S...
InMode Expects Third Quarter 2023 Revenue Between $122.8M-$123.0M, Lowering Full-Year 2023 Revenue Guidance to $500M-$510M vs. Original Estimates of $530M-$540M PR Newswire Conference call to be held on Thursday, Nov. 2, 2023, at 8:30 a.m. Eastern Time YOKNEA...
2023-10-09 16:59:45 ET More on InMode InMode: Strong Net Cash Position Sets The Stage For Opportunistic Buybacks InMode: Bullish Support Failed To Materialize InMode: Be Greedy When Others Are Fearful For further details see: InMode does not expect produc...
InMode Affirms Safety of Management, Employees and Production Sites PR Newswire YOKNEAM, Israel , Oct. 9, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, addressed today the status of th...
News, Short Squeeze, Breakout and More Instantly...
DOMA Perpetual Sends Letter to the Board of Directors of InMode Urging the Execution of a 40% Tender Offer PR Newswire Believes InMode's Cash Balance of Roughly 55% of its Market Cap is Grossly Inefficient Asserts the Current Valuation Offers an Unprecedented Oppo...
2024-07-23 06:00:08 ET Matthew Taylor from Jefferies issued a price target of $19.00 for INMD on 2024-07-23 05:00:00. The adjusted price target was set to $19.00. At the time of the announcement, INMD was trading at $17.75. The overall price target consensus is at $34.50...
Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling PR Newswire IRVINE, Calif. , July 17, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technolog...